Mounjaro has quickly become one of the most exciting weight loss medications available in Canada, and the clinical data backs up the hype. It contains tirzepatide, the only drug that activates both GIP and GLP-1 receptors at the same time. In head-to-head comparisons with semaglutide, it has consistently shown greater weight loss. I put together this guide to explain what makes Mounjaro different, what the trial data actually shows, and what Canadian patients need to know in 2026.
This page focuses on the science, the clinical evidence, and the practical details specific to Mounjaro. For deep dives on cost, savings programs, and how to get a prescription, I have linked to dedicated pages throughout.
What Is Mounjaro (Tirzepatide)?
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. It was originally approved in Canada for type 2 diabetes and has since received approval for chronic weight management. Unlike semaglutide (Ozempic/Wegovy), which only targets GLP-1 receptors, tirzepatide is a "twincretin" that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.
This dual mechanism is not just a marketing distinction. It represents a genuinely different pharmacological approach and appears to be why Mounjaro produces greater weight loss than single-receptor drugs. Tirzepatide is delivered as a once-weekly subcutaneous injection, similar to Ozempic and Wegovy.
Eli Lilly markets tirzepatide under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both brands are available in Canada, and Eli Lilly Canada operates a Zepbound Savings Card program for eligible Canadian patients.
The Dual GIP/GLP-1 Mechanism: Why It Matters
To understand why Mounjaro outperforms single-target GLP-1 drugs, you need to understand what GIP does and why combining it with GLP-1 activation creates a synergistic effect.
GLP-1 (glucagon-like peptide-1): This is the same receptor that semaglutide targets. Activation reduces appetite, slows gastric emptying, stimulates insulin release, and suppresses glucagon. It is the mechanism behind Ozempic and Wegovy.
GIP (glucose-dependent insulinotropic polypeptide): This is where Mounjaro adds something new. GIP is the other major incretin hormone, released from K-cells in the upper small intestine after eating. GIP receptor activation enhances insulin secretion, acts on fat tissue to improve fat metabolism and energy expenditure, acts on the brain to reduce appetite through pathways distinct from GLP-1, and may help reduce fat accumulation in the liver.
The combination creates effects that neither hormone achieves alone. Think of it as two complementary pathways converging on the same goals through different cellular mechanisms. Research suggests the GIP component may also explain why some patients tolerate Mounjaro's GI side effects better than pure GLP-1 drugs, though this is still being studied.
Tirzepatide's molecular structure is based on the GIP hormone backbone with modifications that allow it to activate both receptors. The ratio of activity favours GIP over GLP-1, which is the opposite of what you might expect given the prominence of GLP-1 drugs. This design choice by Eli Lilly researchers appears to have paid off in the clinical results.
SURMOUNT Trial Results: 22% Average Weight Loss
The SURMOUNT trial program is to Mounjaro what the STEP program was to Wegovy. These were large, rigorous, randomized controlled trials that established tirzepatide as the most effective weight loss medication ever studied. Here are the headline results:
| Trial | Participants | Duration | Tirzepatide 15 mg Weight Loss | Placebo Weight Loss |
|---|---|---|---|---|
| SURMOUNT-1 | 2,539 adults without diabetes | 72 weeks | 22.5% | 2.4% |
| SURMOUNT-2 | 938 adults with type 2 diabetes | 72 weeks | 14.7% | 3.2% |
| SURMOUNT-3 | 579 adults after intensive lifestyle intervention | 72 weeks | 26.6% (total with lead-in) | Regained weight |
| SURMOUNT-4 | 670 adults (continuation vs. withdrawal) | 88 weeks | Maintained loss | Regained about 14% |
In SURMOUNT-1, the average starting weight was about 105 kg (231 lbs). A 22.5% loss means roughly 23.6 kg (52 lbs) over 72 weeks. More than half of participants on the 15 mg dose lost 20% or more of their body weight, and about 37% lost 25% or more. These numbers were previously only achievable with bariatric surgery.
SURMOUNT-3 is particularly striking because participants first went through a 12-week intensive lifestyle program before being randomized to tirzepatide or placebo. The combined effect produced an average total weight loss of 26.6%. SURMOUNT-4 showed that stopping tirzepatide led to about 14% regain, confirming that ongoing use is needed for sustained results.
The SURPASS Trials (Diabetes)
| Trial | Comparison | HbA1c Reduction (15 mg) | Weight Loss (15 mg) |
|---|---|---|---|
| SURPASS-1 | vs. placebo | 2.07% | 9.5 kg |
| SURPASS-2 | vs. semaglutide 1 mg | 2.30% (vs 1.86%) | 12.4 kg (vs 6.2 kg) |
| SURPASS-3 | vs. insulin degludec | 2.37% | 12.9 kg |
| SURPASS-4 | vs. insulin glargine | 2.58% | 11.7 kg |
SURPASS-2 is the most important for comparison purposes because it directly tested tirzepatide against semaglutide (Ozempic 1 mg). Tirzepatide 15 mg achieved double the weight loss and a greater HbA1c reduction. While this compared against Ozempic's diabetes dose rather than Wegovy's weight loss dose, it was still a decisive win for tirzepatide.
Mounjaro Dosing Schedule
Mounjaro uses a gradual dose escalation similar to Wegovy, though the steps are different:
| Period | Dose | Duration |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg weekly | 4 weeks (starting dose) |
| Weeks 5 to 8 | 5 mg weekly | 4 weeks |
| Weeks 9 to 12 | 7.5 mg weekly | 4 weeks (optional step) |
| Weeks 13 to 16 | 10 mg weekly | 4 weeks |
| Weeks 17 to 20 | 12.5 mg weekly | 4 weeks (optional step) |
| Week 21 onward | 15 mg weekly | Maintenance |
The maximum dose is 15 mg per week, but your doctor may keep you at a lower dose if you are responding well. Many patients achieve good results at 10 mg. Mounjaro comes in pre-filled single-dose pens. Inject once weekly, on the same day, at any time. Rotate injection sites between abdomen, thigh, or upper arm.
If you miss a dose, take it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip that dose and resume your regular schedule.
Mounjaro vs Ozempic: Head-to-Head Data
This is the comparison most patients and doctors want to see. While there is no single trial that directly compared Mounjaro 15 mg against Wegovy 2.4 mg, we have strong indirect evidence and the SURPASS-2 direct comparison at diabetes doses.
| Metric | Mounjaro (Tirzepatide 15 mg) | Ozempic/Wegovy (Semaglutide 2.4 mg) |
|---|---|---|
| Average weight loss (non-diabetic) | 22.5% (SURMOUNT-1) | 14.9% (STEP 1) |
| Patients losing 20%+ body weight | 57% | 32% |
| Patients losing 10%+ body weight | 85% | 69% |
| Mechanism | Dual GIP + GLP-1 | GLP-1 only |
| Cardiovascular outcomes trial | SURPASS-CVOT (ongoing) | SELECT (20% reduction in MACE — major adverse cardiovascular events) |
On weight loss alone, Mounjaro clearly outperforms semaglutide. The gap of about 7 to 8 percentage points is clinically meaningful. For a 100 kg person, that is the difference between losing 15 kg and losing 22.5 kg. However, semaglutide currently has an advantage in cardiovascular evidence. The SELECT trial proved that semaglutide 2.4 mg reduces heart attacks, strokes, and cardiovascular death by 20%. Mounjaro's SURPASS-CVOT is still ongoing.
Who Qualifies for Mounjaro in Canada?
Type 2 diabetes: Adults who need additional glycemic control, as an adjunct to diet and exercise.
Chronic weight management: Adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.
Contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, known hypersensitivity to tirzepatide, and a history of pancreatitis. Women who are pregnant or planning pregnancy should not use Mounjaro.
What to Expect Month by Month
Weeks 1 to 4 (2.5 mg): The starting dose is low, so effects are usually mild. Some appetite reduction. Minimal weight loss, typically 1 to 2 kg. Nausea may occur but is usually manageable.
Weeks 5 to 8 (5 mg): Appetite suppression kicks in more noticeably. Weight loss accelerates. Many patients report that portion sizes naturally decrease without feeling deprived.
Weeks 9 to 16 (7.5 to 10 mg): This is where the momentum really builds. Weight loss is typically 1 to 2 lbs per week. By week 12, most patients have lost 5% to 8% of their starting weight. Food noise often decreases significantly.
Weeks 17 to 24 (12.5 to 15 mg): Approaching or reaching the maintenance dose. Weight loss continues at a steady pace. Patients often notice improvements in blood pressure, blood sugar, energy levels, and joint pain.
Months 6 to 12: Peak weight loss velocity. Most of the total loss occurs during this window. After 12 months, weight stabilizes and ongoing Mounjaro use is needed to maintain the loss.
Side Effects Overview
Mounjaro's side effect profile is similar to other GLP-1 based medications, with gastrointestinal symptoms being most common. From SURMOUNT-1 data: nausea affects about 31% (compared to roughly 44% with Wegovy), diarrhea about 23%, constipation about 11%, vomiting about 12%, and decreased appetite about 20%.
Interestingly, the GI side effect rates with Mounjaro appear somewhat lower than with semaglutide, despite the greater weight loss. Serious rare side effects include pancreatitis, gallbladder problems, and potential thyroid concerns. A dedicated side effects page with management strategies is coming soon.
Cost Overview
Mounjaro costs roughly $300 to $500 per month in Canada without insurance, depending on the dose. Insurance coverage for the weight management indication remains inconsistent. Provincial formularies are gradually adding coverage, primarily for the type 2 diabetes indication.
Read the full guide: Mounjaro Cost in Canada: Complete Pricing and Coverage Guide
Generic Semaglutide at In-Person Canadian Pharmacies
Cash retail prices for generic semaglutide at Canadian pharmacies are now coming in below the telehealth alternatives, based on early Canadian consumer reports. Costco Pharmacy is the lowest reliable option at roughly $88 to $99 per month (confirmed pickups: $88.88 GTA, $88 Ontario, $99 Laval, $91 Medicine Hat). Walmart and Loblaws No Frills typically come in around $95 to $110 per month. Shoppers Drug Mart, Rexall and London Drugs are running roughly $100 to $120 per month (one Halifax-area Shoppers fill reported $113 for the 0.25mg starter dose). Apotex's Apo-Semaglutide Injection began shipping to Canadian pharmacies on May 20, 2026, with Dr. Reddy's generic also launching in May 2026.
That makes in-person pharmacies — especially Costco — meaningfully cheaper than telehealth providers for generic semaglutide. Felix Health and Hims Canada both list $149 per month all-in for the same generic Apo-Semaglutide on their public pricing pages. For most Canadians with a valid prescription, walking it into a local pharmacy is now the cheapest reliable path.
Pricing context: per the Globe and Mail, Apotex's published wholesale price is $78.14 for a four-week supply — roughly one-third of brand-name Ozempic's $240.48 wholesale price. Retail estimates above reflect that wholesale plus each chain's standard dispensing fee and markup. See also coverage from CBC News on the Canadian launch. Note: This generic launch is for semaglutide (Ozempic-equivalent), not tirzepatide. Generic Mounjaro is still years away — Eli Lilly's patents on tirzepatide extend through 2036+. Under the pan-Canadian Pharmaceutical Alliance framework, the maximum public drug plan price for generic semaglutide is approximately $114 per four-week supply with two manufacturers approved, dropping to roughly $80 once a third manufacturer launches.
The myMounjaro Savings Card
Eli Lilly offers the myMounjaro savings card program in Canada, which can significantly reduce out-of-pocket costs for eligible patients. The program is designed for patients who have some private insurance coverage but face high copays, as well as those starting Mounjaro for the first time.
Eligibility and savings amounts change periodically, so check the current terms on the Eli Lilly Canada website or ask your pharmacist. The savings card is typically applied at the pharmacy counter and can be combined with your existing insurance. A detailed breakdown of the myMounjaro program is coming soon as a dedicated page.
Online Providers Cost Comparison
Most Canadians now access Mounjaro through telehealth providers rather than in-person clinics. Below is how the main Canadian online providers compare for Mounjaro (tirzepatide) prescribing, with MyRocky now our highest-rated GLP-1 provider overall.
| Provider | Mounjaro Monthly Cost | Consultation Fee | Coverage | Learn More |
|---|---|---|---|---|
| MyRocky | $290 to $440 by dose (2.5 mg to 10 mg pen) | $99 one-time (includes lab work and first prescription) | All 10 provinces (including QC and NB) | Visit MyRocky |
| Felix Health | $800 to $1,000 (savings card may apply) | Free (first), $40 follow-up | All provinces except QC and NB | Visit Felix |
| Maple | $800 to $1,000 (savings card may apply) | $69 one-time | All provinces + territories | Visit Maple |
| Hims Canada | Generic semaglutide available — pricing on consult | Included in plan | ON, BC, AB (expanding 2026) | Visit Hims |
| Raven | Pricing on assessment | Pricing on assessment | 9 provinces | Visit Raven |
MyRocky is our highest-rated Canadian GLP-1 telehealth provider in 2026 (9.4/10). MyRocky ships Health Canada-approved Mounjaro to all 10 provinces (including Quebec and New Brunswick where Felix and Hims do not operate), operates its own LegitScript-certified pharmacy in Mississauga, and employs Canadian-licensed MDs, nurse practitioners and pharmacists. The $99 one-time consultation includes lab work and the first prescription. Read our full MyRocky review.
FAQ
Is Mounjaro better than Ozempic for weight loss? On average, yes. Clinical trials show about 22% body weight loss with Mounjaro 15 mg versus about 15% with semaglutide 2.4 mg. However, individual responses vary, and semaglutide has stronger cardiovascular outcomes evidence from the SELECT trial.
Is Mounjaro available in Canada? Yes. Mounjaro is approved by Health Canada for both type 2 diabetes and chronic weight management. Supply has been improving, though spot shortages can still occur.
How is Mounjaro different from semaglutide? Mounjaro contains tirzepatide, which activates both GIP and GLP-1 receptors. Semaglutide (Ozempic/Wegovy) only activates GLP-1 receptors. This dual mechanism appears to be why Mounjaro produces greater weight loss.
Do I need to take Mounjaro forever? Current evidence (SURMOUNT-4) shows that stopping Mounjaro leads to significant weight regain. Most obesity medicine experts consider it a chronic medication, similar to drugs for blood pressure or cholesterol.
Can I switch from Ozempic to Mounjaro? Yes, many patients have successfully switched. Your doctor will determine the appropriate starting dose. Typically you would start at 2.5 mg and titrate up, though some doctors begin at a higher dose for patients already on high-dose semaglutide.
What makes the dual mechanism more effective? GIP and GLP-1 work through complementary but distinct pathways. GIP enhances fat metabolism and insulin secretion through mechanisms that GLP-1 does not, while GLP-1 has stronger effects on gastric emptying and glucagon suppression. Together, they produce additive effects that exceed what either achieves alone.
Is Mounjaro covered by insurance in Canada? Coverage varies significantly. Most private insurers and some provincial plans cover Mounjaro for type 2 diabetes. Coverage for weight management is less common but growing. Check with your insurer and see our cost page for strategies to get coverage.
Sources
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216. (SURMOUNT-1)
- Garvey WT, et al. The Lancet. 2023;402(10402):613-626. (SURMOUNT-2)
- Wadden TA, et al. Nature Medicine. 2024;30:3024-3034. (SURMOUNT-3)
- Aronne LJ, et al. JAMA. 2024;331(1):38-48. (SURMOUNT-4)
- Frias JP, et al. NEJM. 2021;385(6):503-515. (SURPASS-2)
- Del Prato S, et al. The Lancet. 2021;398(10313):1811-1824. (SURPASS-4)
- Eli Lilly Canada. Mounjaro (tirzepatide) Canadian Product Monograph. Health Canada.
- Health Canada. Summary Basis of Decision: Mounjaro.
- Finan B, et al. Science Translational Medicine. 2013;5(209):209ra151.
- Diabetes Canada. 2024 Clinical Practice Guidelines.